Literature DB >> 7126419

The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole.

M Dawson, R J Allan, T R Watson.   

Abstract

Following the intravenous administration of a tracer dose (1.7 microgram) of [3H]-mebendazole to a man, an elimination half-life of 1.16 h was observed and the volume of distribution was calculated to be 2.03 l/kg. After oral administration of the same dose, an elimination half-life of 0.74 h was observed. The bioavailability of mebendazole from the solution was found to be 17%.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7126419      PMCID： PMC1427637          DOI： 10.1111/j.1365-2125.1982.tb02008.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  5 in total

1.  Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects.

Authors:  J P Brugmans; D C Thienpont; I van Wijngaarden; O F Vanparijs; V L Schuermans; H L Lauwers
Journal:  JAMA       Date:  1971-07-19       Impact factor: 56.272

2.  Medical treatment for hydatids.

Authors:  T C Beard; M D Rickard; H T Goodman
Journal:  Med J Aust       Date:  1978-06-17       Impact factor: 7.738

3.  Treatment of hepatic hydatid disease with mebedazole: preliminary results in four cases.

Authors:  A Bekhti; J P Schaaps; M Capron; J P Dessaint; F Santoro; A Capron
Journal:  Br Med J       Date:  1977-10-22

4.  Chemotherapy of onchocerciasis: a controlled comparison of mebendazole, levamisole, and diethylcarbamazine.

Authors:  A R Rivas-Alcalá; B M Greene; H R Taylor; A Domíguez-Vázquez; A M Ruvalcaba-Macías; C Lugo-Pfeiffer; C D Mackenzie; F Beltrán
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

5.  Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results.

Authors:  G J Münst; G Karlaganis; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953
  5 in total
  13 in total

1.  Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus.

Authors:  Cong-shan Liu; Hao-bing Zhang; Bin Jiang; Jun-min Yao; Yi Tao; Jian Xue; Ai-dan Wen
Journal:  Parasitol Res       Date:  2012-06-04       Impact factor: 2.289

2.  Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors:  Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal:  Eur J Clin Pharmacol       Date:  2009-06-27       Impact factor: 2.953

3.  Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions.

Authors:  P J Luder; B Siffert; F Witassek; F Meister; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and in Vitro Activity against Cryptococcus neoformans.

Authors:  Yogesh Sutar; Sophie R Fulton; Sagarkumar Paul; Sophie Altamirano; Susmit Mhatre; Hiwa Saeed; Pratikkumar Patel; Sudipta Mallick; Roopal Bhat; Vandana B Patravale; Harsh Chauhan; Kirsten Nielsen; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2021-09-01       Impact factor: 5.084

5.  HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo.

Authors:  Martin Studenovský; Anna Rumlerová; Jiřina Kovářová; Barbora Dvořáková; Ladislav Sivák; Libor Kostka; Daniel Berdár; Tomáš Etrych; Marek Kovář
Journal:  Pharmaceutics       Date:  2022-06-04       Impact factor: 6.525

6.  The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.

Authors:  M Dawson; P A Braithwaite; M S Roberts; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

7.  Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis.

Authors:  F Witassek; R J Allan; T R Watson; W Woodtli; R Ammann; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.

Authors:  F Witassek; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens.

Authors:  P J Luder; F Witassek; K Weigand; J Eckert; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Lack of effect of haemodialysis on mebendazole kinetics: studies in a patient with echinococcosis and renal failure.

Authors:  H Allgayer; J Zähringer; P Bach; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.